Future drug discovery in renin-angiotensin-aldosterone system intervention

References

• Bader M. Tissue renin-angiotensin-aldosterone systems: targets for pharmacological therapy. Annu Rev Pharmacol Toxicol. 2010;50:439–465.
   PubMed Web of Science ®Google Scholar
• Kumar R, Thomas CM, Yong QC, et al. The intracrine renin-angiotensin system. Clin Sci (Lond). 2012;123:273–284.
   PubMed Web of Science ®Google Scholar
• Chappell MC. Biochemical evaluation of the renin-angiotensin system: the good, bad, and absolute? Am J Physiol Heart Circ Physiol. 2016;310:H137–H152.
   PubMed Web of Science ®Google Scholar
• Sevá Pessôa B, van der Lubbe N, Verdonk K, et al. Key developments in renin-angiotensin-aldosterone system inhibition. Nat Rev Nephrol. 2013;9:26–36.
   PubMed Web of Science ®Google Scholar
• Tamargo J, Duarte J, Ruilope LM. New antihypertensive drugs under development. Curr Med Chem. 2015;22:305–342.
   PubMed Web of Science ®Google Scholar
• Mancia G, Fagard R, Narkiewicz K; Task Force Members. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281–1357.
   PubMed Web of Science ®Google Scholar
• López-Sendón J, Swedberg K, McMurray J, et al. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology. Eur Heart J. 2004;25:1454–1470.
   PubMed Web of Science ®Google Scholar
• Rydén L, Grant PJ, Anker SD, et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Diab Vasc Dis Res. 2014;11:133–173.
   PubMed Web of Science ®Google Scholar
• Fox K, Garcia MAA, Ardissino D, et al. Guidelines on the management of stable angina pectoris: executive summary: the task force on the management of stable angina pectoris of the European society of cardiology. Eur Heart J. 2006;27:1341–1381.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al.; Authors/Task Force Members. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:2129–2200.
   PubMed Web of Science ®Google Scholar
• Steg PG, James SK, Atar D, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33:2569–2619.
   PubMed Web of Science ®Google Scholar
• Düsing R. Mega clinical trials which have shaped the RAS intervention clinical practice. Ther Adv Cardiovasc Dis. 2016;10:133–150.
   PubMedGoogle Scholar
• Brugts JJ, van Vark L, Akkerhuis M, et al. Impact of renin-angiotensin system inhibitors on mortality and major cardiovascular endpoints in hypertension: a number-needed-to-treat analysis. Int J Cardiol. 2015;181:425–429.
   PubMed Web of Science ®Google Scholar
• Heran BS, Musini VM, Bassett K, et al. Angiotensin receptor blockers for heart failure. Cochrane Database Syst Rev. 2012;4:CD003040.
   Google Scholar
• Reyes S, Varagic J, Ahmad S, et al. Novel cardiac intracrine mechanisms based on Ang-(1-12)/chymase axis require a revision of therapeutic approaches in human heart disease. Curr Hypertens Rep. 2017;19:16.
   PubMed Web of Science ®Google Scholar
• Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111:2605–2610.
   PubMed Web of Science ®Google Scholar
• Ferrario CM, Ahmad S, Varagic J, et al. Intracrine Ang II functions originate from noncanonical pathways in the human heart. Am J Physiol Heart Circ Physiol. 2016;311:H404–H414.
   PubMed Web of Science ®Google Scholar
• Cook J, Zhang Z, Re RN. In vitro evidence for an intracellular site of angiotensin action. Circ Res. 2001;89:1138–1146.
   PubMed Web of Science ®Google Scholar
• Li XC, Zhuo JL. Proximal tubule-dominant transfer of AT1a receptors induces blood pressure responses to intracellular angiotensin II in AT1a receptor-deficient mice. Am J Physiol Regul Integr Comp Physiol. 2013;304:R588–R598.
   PubMed Web of Science ®Google Scholar
• Rice ASC, Dworkin RH, McCarthy TD, et al.; EMA401-003 Study Group. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet. 2014;383:1637–1647.
   PubMed Web of Science ®Google Scholar
• A two part study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2586881. [ cited 2017 May 10]. Available from: https://www.gsk-clinicalstudyregister.com/files2/GSK-114622-Clinical-Study-Result-Summary.pdf
   Google Scholar
• Petty WJ, Miller AA, McCoy TP, et al. Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone. Clin Cancer Res. 2009;15:7398–7404.
   PubMed Web of Science ®Google Scholar
• Rodgers KE, Oliver J, diZerega GS. Phase I/II dose escalation study of angiotensin 1-7 [A(1-7)] administered before and after chemotherapy in patients with newly diagnosed breast cancer. Cancer Chemother Pharmacol. 2006;57:559–568.
   PubMed Web of Science ®Google Scholar
• Balingit PP, Armstrong DG, Reyzelman AM, et al. NorLeu3-A(1-7) stimulation of diabetic foot ulcer healing: results of a randomized, parallel-group, double-blind, placebo-controlled phase 2 clinical trial. Wound Repair Regen. 2012;20:482–490.
   PubMed Web of Science ®Google Scholar
• Pham H, Schwartz BM, Delmore JE, et al. Pharmacodynamic stimulation of thrombogenesis by angiotensin (1-7) in recurrent ovarian cancer patients receiving gemcitabine and platinum-based chemotherapy. Cancer Chemother Pharmacol. 2013;71:965–967.
   PubMed Web of Science ®Google Scholar
• Savage PD, Lovato J, Brosnihan KB, et al. Phase II Trial of Angiotensin-(1-7) for the treatment of patients with metastatic sarcoma. Sarcoma. 2016;2016:1–7.
   Google Scholar
• Pouleur A-C, Uno H, Prescott MF, et al.; ALLAY Investigators. Suppression of aldosterone mediates regression of left ventricular hypertrophy in patients with hypertension. J Renin Angiotensin Aldosterone Syst. 2011;12:483–490.
   PubMed Web of Science ®Google Scholar
• Parving -H-H, Brenner BM, McMurray JJV, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367:2204–2213.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Bakris GL, Kastelein JJP, et al. Effect of aliskiren on progression of coronary disease in patients with prehypertension the AQUARIUS randomized clinical trial. JAMA. 2013;310:1135–1144.
   PubMed Web of Science ®Google Scholar
• Solomon SD, Shin SH, Shah A, et al.; Aliskiren Study in Post-MI Patients to Reduce Remodeling (ASPIRE) Investigators. Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. Eur Heart J. 2011;32:1227–1234.
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Böhm M, Greene SJ, et al. Effect of aliskiren on post-discharge mortality and heart failure readmissions among patients hospitalized for heart failure the ASTRONAUT randomized trial. JAMA. 2013;309:1125–1135.
   PubMed Web of Science ®Google Scholar
• McMurray JJV, Krum H, Abraham WT, et al.; ATMOSPHERE Committees Investigators. Aliskiren, enalapril, or aliskiren and enalapril in heart failure. N Engl J Med. 2016;374:1521–1532.
   PubMed Web of Science ®Google Scholar
• Scirica B, Morrow D, Bode C, et al. Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43, trial. Eur Heart J. 2010;31:1993–2005.
   PubMed Web of Science ®Google Scholar
• Parving -H-H, Persson F, Lewis JB, et al. AVOID study investigators aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358:2433–2446.
   PubMed Web of Science ®Google Scholar
• Trevena reports TRV027 did not achieve primary or secondary endpoints in BLAST-AHF Phase 2b trial in acute heart failure. [ cited 2017 May 10]. Available from: http://www.businesswire.com/news/home/20160516005387/en/Trevena-Reports-TRV027-Achieve-Primary-Secondary-Endpoints
   Google Scholar
• Brown MJ, Coltart J, Gunewardena K, et al. Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects. Clin Sci (Lond). 2004;107:167–173.
   PubMed Web of Science ®Google Scholar
• Tissot AC, Maurer P, Nussberger J, et al. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebocontrolled phase IIa study. Lancet. 2008;371:821–827.
   PubMed Web of Science ®Google Scholar
• Cytos biotechnology reports biochemical findings from phase IIa study with hypertension vaccine Cyt006–AngQb. [ cited 2016 Dec 27]. Available from: http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=190948
   Google Scholar
• Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34:2453–2463.
   PubMed Web of Science ®Google Scholar
• Filippatos G, Anker SD, Böhm M, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J. 2016;37:2105–2114.
   PubMed Web of Science ®Google Scholar
• Bakris GL, Agarwal R, Chan JC, et al.; Mineralocorticoid receptor antagonist tolerability study–Diabetic Nephropathy (ARTS-DN) study group. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA. 2015;314:884–894.
   PubMed Web of Science ®Google Scholar
• Sato N, Ajioka M, Yamada T, et al.; ARTS-HF Japan study group. A randomized controlled study of finerenone vs. eplerenone in Japanese patients with worsening chronic heart failure and diabetes and/or chronic kidney disease. Circ J. 2016;80:1113–1122.
   PubMed Web of Science ®Google Scholar
• Katayama S, Yamada D, Nakayama M, et al.; ARTS-DN Japan study group. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy. J Diabetes Complications. 2017;31:758–765.
   PubMed Web of Science ®Google Scholar
• Calhoun DA, White WB, Krum H, et al. Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. Circulation. 2011;124:1945–1955.
   PubMed Web of Science ®Google Scholar
• Andersen K, Hartman D, Peppard T, et al. The effects of aldosterone synthase inhibition on aldosterone and cortisol in patients with hypertension: a phase II, randomized, double-blind, placebo-controlled, multicenter study. J Clin Hypertens (Greenwich). 2012;14:580–587.
   PubMed Web of Science ®Google Scholar
• Amar L, Azizi M, Menardet J, et al. Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism. Hypertension. 2010;56:831–838.
   PubMed Web of Science ®Google Scholar
• Karns AD, Bral JM, Hartman D, et al. Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension. J Clin Hypertens (Greenwich). 2013;15:186–192.
   PubMed Web of Science ®Google Scholar
• Bertagna X, Pivonello R, Fleseriu M, et al. LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing’s disease: results from a multicenter, proof-of-concept study. J Clin Endocrinol Metab. 2014;99:1375–1383.
   PubMed Web of Science ®Google Scholar
• Fleseriu M, Pivonello R, Young J, et al. Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing’s disease. Pituitary. 2016;19:138–148.
   PubMed Web of Science ®Google Scholar
• Alexander SPH, Davenport AP, Kelly E, et al. The concise guide to pharmacology 2015/16: G protein-coupled receptors. Br J Pharmacol. 2015;172:5744–5869.
   PubMed Web of Science ®Google Scholar
• Lemarié CA, Schiffrin EL. The angiotensin II type 2 receptor in cardiovascular disease. J Renin Angiotensin Aldosterone Syst. 2010;11:19–31.
   PubMed Web of Science ®Google Scholar
• Sumners C, de Kloet AD, Krause EG, et al. Angiotensin type 2 receptors: blood pressure regulation and end organ damage. Curr Opin Pharmacol. 2015;21:115–121.
   PubMed Web of Science ®Google Scholar
• Unger T, Steckelings UM, dos Santos RAS. The protective arm of the renin angiotensin system. Functional aspects and therapeutic implications. London: Elsevier Academic Press; 2015.
   Google Scholar
• Iyer SN, Chappell MC, Averill DB, et al. Vasodepressor actions of angiotensin-(1-7) unmasked during combined treatment with lisinopril and losartan. Hypertension. 1998;31:699–705.
   PubMed Web of Science ®Google Scholar
• Miura S, Matsuo Y, Kiya Y, et al. Molecular mechanisms of the antagonistic action between AT1 and AT2 receptors. Biochem Biophys Res Commun. 2010;391:85–90.
   PubMed Web of Science ®Google Scholar
• Mogi M, Iwai M, Horiuchi M. New insights into the regulation of angiotensin receptors. Curr Opin Nephrol Hypertens. 2009;18:138–143.
   PubMed Web of Science ®Google Scholar
• Ferrario CM. Angiotensin-converting enzyme 2 and angiotensin-(1-7): an evolving story in cardiovascular regulation. Hypertension. 2006;47:515–521.
   PubMed Web of Science ®Google Scholar
• Santos RAS, Ferreira AJ, Verano-Braga T, et al. Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system. J Endocrinol. 2013;216:R1–R17.
   PubMed Web of Science ®Google Scholar
• Tetzner A, Gebolys K, Meinert C, et al. G-protein-coupled receptor MrgD is a receptor for Angiotensin-(1-7) involving Adenylyl Cyclase, cAMP, and Phosphokinase A. Hypertension. 2016;68:185–194.
   PubMed Web of Science ®Google Scholar
• Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000;87:E1–E9.
   PubMed Web of Science ®Google Scholar
• Santos RA. Angiotensin-(1-7). Hypertension. 2014;63:1138–1147.
   PubMed Web of Science ®Google Scholar
• Solinski HJ, Gudermann T, Breit A. Pharmacology and signaling of MAS-related G protein-coupled receptors. Pharmacol Rev. 2014;66:570–597.
   PubMed Web of Science ®Google Scholar
• Mendoza-Torres E, Oyarzún A, Mondaca-Ruff D, et al. ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension. Ther Adv Cardiovasc Dis. 2015;9:217–237.
   PubMedGoogle Scholar
• Villela D, Leonhardt J, Patel N, et al. Angiotensin type 2 receptor (AT2R) and receptor Mas: a complex liaison. Clin Sci. 2015;128:227–234.
   PubMed Web of Science ®Google Scholar
• Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002;417:822–828.
   PubMed Web of Science ®Google Scholar
• Oparil S, Schmieder RE. New approaches in the treatment of hypertension. Circ Res. 2015;116:1074–1095.
   PubMed Web of Science ®Google Scholar
• Wong DW, Oudit GY, Reich H, et al. Loss of angiotensin-converting enzyme-2 (Ace2) accelerates diabetic kidney injury. Am J Pathol. 2007;171:438–451.
   PubMed Web of Science ®Google Scholar
• Tikellis C, Bialkowski K, Pete J, et al. Angiotensin-converting enzyme 2 is a key modulator of the renin-angiotensin system in cardiovascular and renal disease. Curr Opin Nephrol Hypertens. 2011;20:62–68.
   PubMed Web of Science ®Google Scholar
• Soler MJ, Wysocki J, Batlle D. ACE2 alterations in kidney disease. Nephrol Dial Transplant. 2013;28:2687–2697.
   PubMed Web of Science ®Google Scholar
• Reich HN, Oudit GY, Penninger JM, et al. Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease. Kidney Int. 2008;74:1610–1616.
   PubMed Web of Science ®Google Scholar
• Díez-Freire C, Vázquez J, Correa de Adjounian MF, et al. ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR. Physiol Genomics. 2006;27:12–19.
   PubMed Web of Science ®Google Scholar
• Rentzsch B, Todiras M, Iliescu R, et al. Transgenic angiotensin-converting enzyme 2 overexpression in vessels of SHRSP rats reduces blood pressure and improves endothelial function. Hypertension. 2008;52:967–973.
   PubMed Web of Science ®Google Scholar
• Wysocki J, Ye M, Rodriguez E, et al. Targeting the degradation of Angiotensin II with recombinant Angiotensin-converting enzyme 2: prevention of Angiotensin II-dependent hypertension. Hypertension. 2010;55:90–98.
   PubMed Web of Science ®Google Scholar
• Hernandez Prada JA, Ferreira AJ, Katovich MJ, et al. Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension. 2008;51:1312–1317.
   PubMed Web of Science ®Google Scholar
• Soro-Paavonen A, Gordin D, Forsblom C, et al.; FinnDiane Study Group. Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications. J Hypertens. 2012;30:375–383.
   PubMed Web of Science ®Google Scholar
• Li S, Wang Z, Yang X, et al. Association between circulating angiotensin-converting enzyme 2 and cardiac remodeling in hypertensive patients. Peptides. 2017;90:63–68.
   PubMed Web of Science ®Google Scholar
• Oudit GY, Kassiri Z, Patel MP, et al. Angiotensin II mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice. Cardiovasc Res. 2007;75:29–39.
   PubMed Web of Science ®Google Scholar
• Zhong J, Basu R, Guo D, et al. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation. 2010;122:717–728.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Ohishi M, Katsuya T, et al. Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II. Hypertension. 2006;47:718–726.
   PubMed Web of Science ®Google Scholar
• Kassiri Z, Zhong J, Guo D, et al. Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction. Circ Heart Fail. 2009;2:446–455.
   PubMed Web of Science ®Google Scholar
• Burrell LM, Risvanis J, Kubota E, et al. Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J. 2005;26:369–375.
   PubMed Web of Science ®Google Scholar
• Kim M-A, Yang D, Kida K, et al. Effects of ACE2 inhibition in the post-myocardial infarction heart. J Card Fail. 2010;16:777–785.
   PubMed Web of Science ®Google Scholar
• Zisman LS, Keller RS, Weaver B, et al. Increased angiotensin-(1–7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme Homologue ACE2. Circulation. 2003;108:1707–1712.
   PubMed Web of Science ®Google Scholar
• Goulter AB, Goddard MJ, Allen JC, et al. ACE2 gene expression is up-regulated in the human failing heart. BMC Med. 2004;2:19.
   PubMed Web of Science ®Google Scholar
• Epelman S, Tang WH, Chen SY, et al. Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system. J Am Coll Cardiol. 2008;52:750–754.
   PubMed Web of Science ®Google Scholar
• Epelman S, Shrestha K, Troughton RW, et al. Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes. J Card Fail. 2009;15:565–571.
   PubMed Web of Science ®Google Scholar
• Wang SX, Fu CY, Zou YB, et al. Polymorphisms of angiotensin-converting enzyme 2 gene associated with magnitude of left ventricular hypertrophy in male patients with hypertrophic cardiomyopathy. Chin Med J (Engl). 2008;121:27–31.
   PubMed Web of Science ®Google Scholar
• Lieb W, Graf J, Götz A, et al. Association of angiotensin-converting enzyme 2 (ACE2) gene polymorphisms with parameters of left ventricular hypertrophy in men. Results of the MONICA Augsburg echocardiographic substudy. J Mol Med (Berl). 2006;84:88–96.
   PubMed Web of Science ®Google Scholar
• Patnaik M, Pati P, Swain SN, et al. Association of angiotensin-converting enzyme and angiotensin-converting enzyme-2 gene polymorphisms with essential hypertension in the population of Odisha, India. Ann Hum Biol. 2014;41:145–152.
   PubMed Web of Science ®Google Scholar
• Yang M, Zhao J, Xing L, et al. The association between angiotensin-converting enzyme 2 polymorphisms and essential hypertension risk: a meta-analysis involving 14,122 patients. J Renin Angiotensin Aldosterone Syst. 2015;16:1240–1244.
   PubMed Web of Science ®Google Scholar
• Liu D, Chen Y, Zhang P, et al. Association between circulating levels of ACE2-Ang-(1-7)-MAS axis and ACE2 gene polymorphisms in hypertensive patients. Medicine (Baltimore). 2016;95:e3876.
   PubMed Web of Science ®Google Scholar
• Wu Y-H, Li J-Y, Wang C, et al. The ACE2 G8790A polymorphism: involvement in type 2 diabetes mellitus combined with cerebral stroke. J Clin Lab Anal. 2017;31:e22033.
   Web of Science ®Google Scholar
• Yang W, Huang W, Su S, et al. Association study of ACE2 (angiotensin I-converting enzyme 2) gene polymorphisms with coronary heart disease and myocardial infarction in a Chinese Han population. Clin Sci (Lond). 2006;111:333–340.
   PubMed Web of Science ®Google Scholar
• Patel VB, Zhong J-C, Grant MB, et al. Role of the ACE2/Angiotensin 1-7 Axis of the renin-angiotensin system in heart failure. Circ Res. 2016;118:1313–1326.
   PubMed Web of Science ®Google Scholar
• Ohshima K, Mogi M, Nakaoka H, et al. Possible role of angiotensin-converting enzyme 2 and activation of angiotensin II type 2 receptor by angiotensin-(1-7) in improvement of vascular remodeling by angiotensin II type 1 receptor blockade. Hypertension. 2014;63:e53–e59.
   PubMed Web of Science ®Google Scholar
• Li X, Molina-Molina M, Abdul-Hafez A, et al. Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosis. Am J Physiol Lung Cell Mol Physiol. 2008;295:L178–L185.
   PubMed Web of Science ®Google Scholar
• Shenoy V, Qi Y, Katovich MJ, et al. ACE2, a promising therapeutic target for pulmonary hypertension. Curr Opin Pharmacol. 2011;11:150–155.
   PubMed Web of Science ®Google Scholar
• Shenoy V, Kwon K-C, Rathinasabapathy A, et al. Oral delivery of Angiotensin-converting enzyme 2 and Angiotensin-(1-7) bioencapsulated in plant cells attenuates pulmonary hypertension. Hypertension. 2014;64:1248–1259.
   PubMed Web of Science ®Google Scholar
• Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450–454.
   PubMed Web of Science ®Google Scholar
• Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11:875–879.
   PubMed Web of Science ®Google Scholar
• Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436:112–116.
   PubMed Web of Science ®Google Scholar
• Wan Y, Wallinder C, Plouffe B, et al. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem. 2004;47:5995–6008.
   PubMed Web of Science ®Google Scholar
• Bosnyak S, Welungoda IK, Hallberg A, et al. Stimulation of angiotensin AT2 receptors by the non-peptide agonist, Compound 21, evokes vasodepressor effects in conscious spontaneously hypertensive rats. Br J Pharmacol. 2010;159:709–716.
   PubMed Web of Science ®Google Scholar
• Kemp BA, Howell NL, Gildea JJ, et al. AT2 receptor activation induces natriuresis and lowers blood pressure. Circ Res. 2014;115:388–399.
   PubMed Web of Science ®Google Scholar
• Gelosa P, Pignieri A, Fandriks L, et al. Stimulation of AT2 receptor exerts beneficial effects in stroke-prone rats: focus on renal damage. J Hypertens. 2009;27:2444–2451.
   PubMed Web of Science ®Google Scholar
• Matavelli LC, Huang J, Siragy HM. Angiotensin AT2 receptor stimulation inhibits early renal inflammation in renovascular hypertension. Hypertension. 2011;57:308–313.
   PubMed Web of Science ®Google Scholar
• Kaschina E, Grzesiak A, Li J, et al. Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation. 2008;118:2523–2532.
   PubMed Web of Science ®Google Scholar
• Rompe F, Artuc M, Hallberg A, et al. Direct angiotensin II type 2 receptor stimulation acts antiinflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor {kappa}B. Hypertension. 2010;55:924–931.
   PubMed Web of Science ®Google Scholar
• Lauer D, Slavic S, Sommerfeld M, et al. Angiotensin type 2 receptor stimulation ameliorates left ventricular fibrosis and dysfunction via regulation of tissue inhibitor of matrix metalloproteinase 1/matrix metalloproteinase 9 axis and transforming growth factor b1 in the rat heart. Hypertension. 2014;63:e60–e67.
   PubMed Web of Science ®Google Scholar
• Min L-J, Mogi M, Tsukuda K, et al. Direct stimulation of angiotensin II type 2 receptor initiated after stroke ameliorates ischemic brain damage. Am J Hypertens. 2014;27:1036–1044.
   PubMed Web of Science ®Google Scholar
• Koulis C, Chow BSM, Mckelvey M, et al. AT2R agonist, compound 21, is reno-protective against type 1 diabetic nephropathy. Hypertension. 2015;65:1073–1081.
   PubMed Web of Science ®Google Scholar
• Shao C, Yu L, Gao L. Activation of angiotensin type 2 receptors partially ameliorates streptozotocin-induced diabetes in male rats by islet protection. Endocrinology. 2014;155:793–804.
   PubMed Web of Science ®Google Scholar
• Chow BSM, Koulis C, Krishnaswamy P, et al. The angiotensin II type 2 receptor agonist Compound 21 is protective in experimental diabetes-associated atherosclerosis. Diabetologia. 2016;59:1778–1790.
   PubMed Web of Science ®Google Scholar
• Sabuhi R, Ali Q, Asghar M, et al. Role of the angiotensin II AT2 receptor in inflammation and oxidative stress: opposing effects in lean and obese Zucker rats. Am J Physiol Renal Physiol. 2011;300:F700–F706.
   PubMed Web of Science ®Google Scholar
• Bruce E, Shenoy V, Rathinasabapathy A, et al. Selective activation of angiotensin AT2 receptors attenuates progression of pulmonary hypertension and inhibits cardiopulmonary fibrosis. Br J Pharmacol. 2015;172:2219–2231.
   PubMed Web of Science ®Google Scholar
• Brouwers S, Smolders I, Wainford RD, et al. Hypotensive and sympathoinhibitory responses to selective central AT2 receptor stimulation in spontaneously hypertensive rats. Clin Sci (Lond). 2015;129:81–92.
   PubMed Web of Science ®Google Scholar
• Rehman A, Leibowitz A, Yamamoto N, et al. Angiotensin type 2 receptor agonist compound 21 reduces vascular injury and myocardial fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension. 2012;59:291–299.
   PubMed Web of Science ®Google Scholar
• Paulis L, Becker ST, Lucht K, et al. Direct angiotensin II type 2 receptor stimulation in Nω-nitro-L-arginine-methyl ester-induced hypertension: the effect on pulse wave velocity and aortic remodeling. Hypertension. 2012;59:485–492.
   PubMed Web of Science ®Google Scholar
• Paulis L, Foulquier S, Namsolleck P, et al. Combined angiotensin receptor modulation in the management of cardio-metabolic disorders. Drugs. 2016;76:1–12.
   PubMed Web of Science ®Google Scholar
• Huentelman MJ, Grobe JL, Vazquez J, et al. Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp Physiol. 2005;90:783–789.
   PubMed Web of Science ®Google Scholar
• Patel VB, Bodiga S, Fan D, et al. Cardioprotective effects mediated by angiotensin II type 1 receptor blockade and enhancing angiotensin 1-7 in experimental heart failure in angiotensin-converting enzyme 2-null mice. Hypertension. 2012;59:1195–1203.
   PubMed Web of Science ®Google Scholar
• Zhong J, Guo D, Chen CB, et al. Prevention of angiotensin II-mediated renal oxidative stress, inflammation, and fibrosis by angiotensin-converting enzyme 2. Hypertension. 2011;57:314–322.
   PubMed Web of Science ®Google Scholar
• Dong B, Zhang C, Feng JB, et al. Overexpression of ACE2 enhances plaque stability in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol. 2008;28:1270–1276.
   PubMed Web of Science ®Google Scholar
• der Sarkissian S, Grobe JL, Yuan L, et al. Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology. Hypertension. 2008;51:712–718.
   PubMed Web of Science ®Google Scholar
• Zhao YX, Yin HQ, Yu QT, et al. ACE2 overexpression ameliorates left ventricular remodeling and dysfunction in a rat model of myocardial infarction. Hum Gene Ther. 2010;21:1545–1554.
   PubMed Web of Science ®Google Scholar
• Lo J, Patel VB, Wang Z, et al. Angiotensin-converting enzyme 2 antagonizes angiotensin II-induced pressor response and NADPH oxidase activation in Wistar-Kyoto rats and spontaneously hypertensive rats. Exp Physiol. 2013;98:109–122.
   PubMed Web of Science ®Google Scholar
• Yamazato Y, Ferreira AJ, Hong K-H, et al. Prevention of pulmonary hypertension by angiotensin-converting enzyme-2 gene transfer. Hypertension. 2009;54:365–367.
   PubMed Web of Science ®Google Scholar
• Treml B, Neu N, Kleinsasser A, et al. Recombinant angiotensin-converting enzyme 2 improves pulmonary blood flow and oxygenation in lipopolysaccharide-induced lung injury in piglets. Crit Care Med. 2010;38:596–601.
   PubMed Web of Science ®Google Scholar
• Patel VB, Bodiga S, Basu R, et al. Loss of angiotensin-converting enzyme-2 exacerbates diabetic cardiovascular complications and leads to systolic and vascular dysfunction: a critical role of the angiotensin II/AT1 receptor axis. Circ Res. 2012;110:1322–1335.
   PubMed Web of Science ®Google Scholar
• Oudit GY, Liu GC, Zhong J, et al. Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes. 2010;59:529–538.
   PubMed Web of Science ®Google Scholar
• Oudit GY, Penninger JM. Recombinant human angiotensin-converting enzyme 2 as a new renin-angiotensin system peptidase for heart failure therapy. Curr Heart Fail Rep. 2011;8:176–183.
   PubMedGoogle Scholar
• Haschke M, Schuster M, Poglitsch M, et al. Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects. Clin Pharmacokinet. 2013;52:783–792.
   PubMed Web of Science ®Google Scholar
• Ferreira AJ, Shenoy V, Qi Y, et al. Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases. Exp Physiol. 2011;96:287–294.
   PubMed Web of Science ®Google Scholar
• Kulemina LV, Ostrov DA. Prediction of off-target effects on angiotensin-converting enzyme 2. J Biomol Screen. 2011;16:878–885.
   PubMedGoogle Scholar
• Shenoy V, Gjymishka A, Jarajapu YP, et al. Diminazene attenuates pulmonary hypertension and improves angiogenic progenitor cell functions in experimental models. Am J Respir Crit Care Med. 2013;187:648–657.
   PubMed Web of Science ®Google Scholar
• Haber PK, Ye M, Wysocki J, et al. Angiotensin-converting enzyme 2-independent action of presumed angiotensin-converting enzyme 2 activators: studies in vivo, ex vivo, and in vitro. Hypertension. 2014;63:774–782.
   PubMed Web of Science ®Google Scholar
• Lula I, Denadai AL, Resende JM, et al. Study of angiotensin-(1-7) vasoactive peptide and its beta-cyclodextrin inclusion complexes: complete sequence-specific NMR assignments and structural studies. Peptides. 2007;28:2199–2210.
   PubMed Web of Science ®Google Scholar
• de Vries L, Reitzema-Klein CE, Meter-Arkema A, et al. Oral and pulmonary delivery of thioether-bridged angiotensin-(1–7). Peptides. 2010;31:893–898.
   PubMed Web of Science ®Google Scholar
• Kluskens LD, Nelemans SA, Rink R, et al. Angiotensin-(1-7) with thioether bridge: an angiotensin-converting enzyme-resistant, potent angiotensin-(1-7) analog. J Pharmacol Exp Ther. 2009;328:849–854.
   PubMed Web of Science ®Google Scholar
• Rodgers KE, Bolton LL, Verco S, et al. NorLeu3-Angiotensin-(1-7) [DSC127] as a therapy for the healing of diabetic foot ulcers. Adv Wound Care (New Rochelle). 2015;4:339–345.
   PubMed Web of Science ®Google Scholar
• Nguyen G, Muller DN. The biology of the (pro)renin receptor. J Am Soc Nephrol. 2010;21:18–23.
   PubMed Web of Science ®Google Scholar
• Duggan ST, Chwieduk CM, Curran MP. Aliskiren: a review of its use as monotherapy and as combination therapy in the management of hypertension. Drugs. 2010;70:2011–2014.
   PubMed Web of Science ®Google Scholar
• Ichihara A, Kaneshiro Y, Takemitsu T, et al. Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension. Hypertension. 2006;47:894–900.
   PubMed Web of Science ®Google Scholar
• Wright JW, Harding JW. The brain renin-angiotensin system: a diversity of functions and implications for CNS diseases. Pflugers Arch. 2013;465:133–151.
   PubMed Web of Science ®Google Scholar
• Marc Y, Gao J, Balavoine F, et al. Central antihypertensive effects of orally active aminopeptidase A inhibitors in spontaneously hypertensive rats. Hypertension. 2012;60:411–418.
   PubMed Web of Science ®Google Scholar
• Gao J, Marc Y, Iturrioz X, et al. A new strategy for treating hypertension by blocking the activity of the brain renin- angiotensin system with aminopeptidase A inhibitors. Clin Sci (Lond). 2014;127:135–148.
   PubMed Web of Science ®Google Scholar
• Balavoine F, Azizi M, Bergerot D, et al. Randomised, double-blind, placebo-controlled, dose-escalating phase I study of QGC001, a centrally acting aminopeptidase a inhibitor prodrug. Clin Pharmacokinet. 2014;53:385–395.
   PubMed Web of Science ®Google Scholar
• Violin JD, Soergel DG, Boerrigter G, et al. GPCR biased ligands as novel heart failure therapeutics. Trends Cardiovasc Med. 2013;23:242–249.
   PubMed Web of Science ®Google Scholar
• Boerrigter G, Soergel DG, Violin JD, et al. TRV120027, a novel beta-arrestin biased ligand at the angiotensin II type I receptor, unloads the heart and maintains renal function when added to furosemide in experimental heart failure. Circ Heart Failure. 2012;5:627–634.
   PubMed Web of Science ®Google Scholar
• Galandrin S, Denis C, Boularan C, et al. Cardioprotective angiotensin-(1-7) peptide acts as a natural-biased ligand at the angiotensin II type 1 receptor. Hypertension. 2016;68:1365–1374.
   PubMed Web of Science ®Google Scholar
• Tojo H, Urata H. Chymase inhibition and cardiovascular protection. Cardiovasc Drugs Ther. 2013;27:139–143.
   PubMed Web of Science ®Google Scholar
• Takai S, Jin D. Improvement of cardiovascular remodelling by chymase inhibitor. Clin Exp Pharmacol Physiol. 2016;43:387–393.
   PubMed Web of Science ®Google Scholar
• Urata H, Healy B, Stewart RW, et al. Ang II forming pathways in normal and failing human hearts. Circ Res. 1990;66:883–890.
   PubMed Web of Science ®Google Scholar
• Nagata S, Kato J, Sasaki K, et al. Isolation and identification of proangiotensin-12, a possible component of the renin-angiotensin system. Biochem Biophys Res Commun. 2006;350:1026–1031.
   PubMed Web of Science ®Google Scholar
• Nagata S, Varagic J, Kon ND, et al. Differential expression of the angiotensin-(1-12)/chymase axis in human atrial tissue. Ther Adv Cardiovasc Dis. 2015;9:168–180.
   PubMedGoogle Scholar
• Wei -C-C, Hase N, Inoue Y, et al. Mast cell chymase limits the cardiac efficacy of Ang I-converting enzyme inhibitor therapy in rodents. J Clin Invest. 2010;120:1229–1239.
   PubMed Web of Science ®Google Scholar
• Nagata S, Hatakeyama K, Asami M, et al. Big endothelin-25: a novel glycosylated angiotensin-related peptide isolated from human urine. Biochem Biophys Res Commun. 2013;441:757–762.
   PubMed Web of Science ®Google Scholar
• Kellici TF, Tzakos AG, Mavromoustakos T. Rational drug design and synthesis of molecules targeting the angiotensin II type 1 and type 2 receptors. Molecules. 2015;20:3868–3869.
   PubMed Web of Science ®Google Scholar
• Ruilope LM, Dukat A, Böhm M, et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375:1255–1266.
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Packer M, Desai AS, et al.; for the PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.
   PubMed Web of Science ®Google Scholar
• Desai AS, McMurray JJV, Packer M, et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J. 2015;36:1990–1997.
   PubMed Web of Science ®Google Scholar
• Bairwa M, Pilania M, Gupta V, et al. Hypertension Vaccine may be a boon to millions in developing world. Hum Vaccin Immunother. 2014;10:708–713.
   PubMed Web of Science ®Google Scholar
• Li LD, Tian M, Liao YH, et al. Effect of active immunization against angiotensin II type 1 (AT1) receptor on hypertension and arterial remodelling in spontaneously hypertensive rats (SHR). Indian J Med Res. 2014;139:619–624.
   PubMed Web of Science ®Google Scholar
• Nakagami F, Koriyama H, Nakagami H, et al. Decrease in blood pressure and regression of cardiovascular complications by angiotensin II vaccine in mice. PLoS One. 2013;8:e60493.
   PubMed Web of Science ®Google Scholar
• Cachofeiro V, López-Andrés N, Miana M, et al. Aldosterone and the cardiovascular system: a dangerous association. Horm Mol Biol Clin Investig. 2010;4:539–548.
   PubMedGoogle Scholar
• Tamargo J, Solini A, Ruilope LM. Comparison of agents that affect aldosterone action. Semin Nephrol. 2014;34:285–306.
   PubMed Web of Science ®Google Scholar
• Lother A, Moser M, Bode C, et al. Mineralocorticoids in the heart and vasculature: new insights for old hormones. Annu Rev Pharmacol Toxicol. 2015;55:289–312.
   PubMed Web of Science ®Google Scholar
• Ferrario CM, Schiffrin EL. Role of mineralocorticoid receptor antagonists in cardiovascular disease. Circ Res. 2015;116:206–213.
   PubMed Web of Science ®Google Scholar
• Jaisser F, Farman N. Emerging roles of the mineralocorticoid receptor in pathology: toward new paradigms in clinical pharmacology. Pharmacol Rev. 2016;68:49–75.
   PubMed Web of Science ®Google Scholar
• Calhoun DA. Hyperaldosteronism as a common cause of resistant hypertension. Annu Rev Med. 2013;64:233–234.
   PubMed Web of Science ®Google Scholar
• Pitt B, Pedro Ferreira J, Zannad F. Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectives. Eur Heart J Cardiovasc Pharmacother. 2017;3:48–57.
   PubMed Web of Science ®Google Scholar
• Fraccarollo D, Berger S, Galuppo P, et al. Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation. 2011;123:400–408.
   PubMed Web of Science ®Google Scholar
• Ivanes F, Susen S, Mouquet F, et al. Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure. Eur Heart J. 2012;33:191–202.
   PubMed Web of Science ®Google Scholar
• Tsai C-T, Chiang F-T, Tseng C-D, et al. Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation. J Am Coll Cardiol. 2010;55:758–770.
   PubMed Web of Science ®Google Scholar
• Pitt B, Pitt GS. Added benefit of mineralocorticoid receptor blockade in the primary prevention of sudden cardiac death. Circulation. 2007;115:2976–2982.
   PubMed Web of Science ®Google Scholar
• Garg R, Adler GK. Aldosterone and the mineralocorticoid receptor: risk factors for cardiometabolic disorders. Curr Hypertens Rep. 2015;17:52.
   PubMed Web of Science ®Google Scholar
• Bertocchio J-P, Warnock DG, Jaisser F. Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease. Kidney Int. 2011;79:1051–1060.
   PubMed Web of Science ®Google Scholar
• Funder JW. Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine. Integr Blood Press Control. 2013;6:129–138.
   PubMedGoogle Scholar
• McManus F, McInnes GT, Connell JMC. Drug Insight: eplerenone, a mineralocorticoid-receptor antagonist. Nat Clin Pract Endocrinol Metab. 2008;4:44–52.
   PubMedGoogle Scholar
• Kolkhof P, Nowack C, Eitner F. Nonsteroidal antagonists of the mineralocorticoid receptor. Curr Opin Nephrol Hypertens. 2015;24:417–424.
   PubMed Web of Science ®Google Scholar
• Yang J, Fuller PJ, Morgan J, et al. GEMIN4 functions as a coregulator of the mineralocorticoid receptor. J Mol Endocrinol. 2015;54:149–160.
   PubMed Web of Science ®Google Scholar
• Fuller PJ. Novel interactions of the mineralocorticoid receptor. Mol Cell Endocrinol. 2015;408:33–37.
   PubMed Web of Science ®Google Scholar
• Bärfacker L, Kuhl A, Hillisch A, et al. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem. 2012;7:1385–1403.
   PubMed Web of Science ®Google Scholar
• Fagart J, Hillisch A, Huyet J, et al. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem. 2010;285:29932–29940.
   PubMed Web of Science ®Google Scholar
• Azizi M, Amar L, Menard J. Aldosterone synthase inhibition in humans. Nephrol Dial Transplant. 2013;28:36–43.
   PubMed Web of Science ®Google Scholar
• Schumacher CD, Steele RE, Brunner HR. Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy. J Hypertens. 2013;31:2085–2093.
   PubMed Web of Science ®Google Scholar
• Abdel-Magid AF. Aldosterone synthase inhibitors: targeting chronic kidney disease and diabetic nephropathy. ACS Med Chem Lett. 2013;4:157–158.
   PubMed Web of Science ®Google Scholar
• Zimmer C, Hafner M, Zender M, et al. N-(Pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2). Bioorg Med Chem Lett. 2011;21:186–190.
   PubMed Web of Science ®Google Scholar
• Yin L, Hu Q, Emmerich J, et al. Novel pyridyl- or isoquinolinyl-substituted indolines and indoles as potent and selective aldosterone synthase inhibitors. J Med Chem. 2014;57:5179–5189.
   PubMed Web of Science ®Google Scholar
• Gobbi S, Hu Q, Negri M, et al. Modulation of cytochromes P450 with xanthone-based molecules: from aromatase to aldosterone synthase and steroid 11β-hydroxylase inhibition. J Med Chem. 2013;56:1723–1729.
   PubMed Web of Science ®Google Scholar
• Martin RE, Lehmann J, Alzieu T, et al. Synthesis of annulated pyridines as inhibitors of aldosterone synthase (CYP11B2). Org Biomol Chem. 2016;14:5922–5927.
   PubMed Web of Science ®Google Scholar
• Petrilli WL, Hoyt SB, London C, et al. Discovery of spirocyclic aldosterone synthase inhibitors as potential treatments for resistant hypertension. ACS Med Chem Lett. 2017;8:128–132.
   PubMed Web of Science ®Google Scholar
• Tamargo J, Ruilope LM. Investigational calcium channel blockers for the treatment of hypertension. Expert Opin Investig Drugs. 2016;25:1295–1309.
   PubMed Web of Science ®Google Scholar
• Zimmerman D, Burns KD. Angiotensin-(1-7) in kidney disease: a review of the controversies. Clin Sci (Lond). 2012;123:333–346.
   PubMed Web of Science ®Google Scholar
• Schindler C, Bramlage P, Kirch W, et al. Role of the vasodilator peptide angiotensin-(1-7) in cardiovascular drug therapy. Vasc Health Risk Manag. 2007;3:125–137.
   PubMedGoogle Scholar
• Kellici TF, Liapakis G, Tzakos AG, et al. Pharmaceutical compositions for antihypertensive treatments: a patent review. Expert Opin Ther Pat. 2015;25:1305–1317.
   PubMed Web of Science ®Google Scholar